Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Psychotic Disorders AND Schizophrenia AND Olanzapine

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    24 result(s) found for: Psychotic Disorders AND Schizophrenia AND Olanzapine. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2008-005019-16 Sponsor Protocol Number: ROCKSAN Start Date*: 2009-03-19
    Sponsor Name:AMC- academisch psychiatrisch centrum
    Full Title: Randomized Olanzapine Clozapine Key study on Schizophrenia and Addiction in the Netherlands (ROCKSAN)
    Medical condition: A multi-centre prospective, randomized, double blind designed study examining the effectiveness and costs of clozapine compared to olanzapine in patients with schizophrenia or related psychotic dis...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-003569-12 Sponsor Protocol Number: 16159A Start Date*: 2016-05-18
    Sponsor Name:H. Lundbeck A/S
    Full Title: Interventional, randomised, double-blind, active-controlled, fixed-dose study of Lu AF35700 in patients with Treatment-resistant Schizophrenia
    Medical condition: Treatment-resistant Schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004873 10072913 Treatment-resistant schizophrenia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) EE (Completed) FI (Completed) CZ (Completed) SK (Completed) BG (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2021-003588-85 Sponsor Protocol Number: PSYCHIC Start Date*: 2022-01-11
    Sponsor Name:UCLouvain
    Full Title: Individualized care with antipsychotics in patients suffering from schizophrenia spectrum disorders- How to conciliate plasma concentrations, clinical response and genetic factors ?
    Medical condition: Schizophrenia, schizoaffective disorders, psychosis not otherwise specified, and dellusional disorders
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2014-003834-21 Sponsor Protocol Number: 80-83600-98-10086 Start Date*: 2016-09-23
    Sponsor Name:Erasmus Medical Center Rotterdam
    Full Title: Effectiveness of penfluridol (oral long acting neuroleptic) as compared to second generation oral neuroleptics in psychotic disorder patients: an open label randomized controlled trial.
    Medical condition: Psychotic disorders
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2004-001376-39 Sponsor Protocol Number: 25520 Start Date*: 2004-12-14
    Sponsor Name:NV Organon
    Full Title: Long-term efficacy and safety evaluation of asenapine (10-20 mg/day) in subjects with schizophrenia or schizoaffective disorder, in a multicenter trial using olanzapine (10-20 mg/day) as a control.
    Medical condition: schizophrenia or schizoaffective disorder
    Disease: Version SOC Term Classification Code Term Level
    7.0 10039628 HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) ES (Prematurely Ended) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2018-000178-31 Sponsor Protocol Number: TREATMENT-patients Start Date*: 2018-05-23
    Sponsor Name:Fundación para la Investigación e Innovación Biosanitaria de Asturias (FINBA)
    Full Title: Metabolic Dysfunctions Associated with Pharmacological Treatment of Schizophrenia
    Medical condition: Schizophrenia
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-000053-27 Sponsor Protocol Number: MELIA Start Date*: 2020-07-09
    Sponsor Name:UMC Utrecht
    Full Title: The MEtformin-LIfestyle in Antipsychotic users trial (MELIA): optimizing the use of metformin in the management of antipsychotic-induced weight gain.
    Medical condition: Antipsychotic-induced weight gain (AiWG)
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-020185-19 Sponsor Protocol Number: KP7242114 Start Date*: 2011-05-30
    Sponsor Name:University Medical Center Utrecht
    Full Title: Optimization of Treatment and Management of Schizophrenia in Europe
    Medical condition: Schizophrenia ICD-10 code F20 or schizophreniform disorder ICD-10 code F23.1
    Disease: Version SOC Term Classification Code Term Level
    16.1 10037175 - Psychiatric disorders 10039626 Schizophrenia PT
    16.1 10037175 - Psychiatric disorders 10039647 Schizophreniform disorder PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) ES (Prematurely Ended) NL (Prematurely Ended) CZ (Completed) DK (Prematurely Ended) AT (Completed) BE (Completed) IT (Completed) BG (Completed) RO (Suspended by CA)
    Trial results: View results
    EudraCT Number: 2004-000986-37 Sponsor Protocol Number: F1D-MC-HGKB Start Date*: 2004-11-26
    Sponsor Name:Eli Lilly and Company Limited
    Full Title: An Open-Label Study of Intramuscular Olanzapine Depot in Patients With Schizophrenia or Schizoaffective Disorder
    Medical condition: Schizophrenia or Schizoaffective Disorder
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) CZ (Completed) ES (Completed) SE (Completed) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-022307-22 Sponsor Protocol Number: BergenPsychosisProject2 Start Date*: 2011-04-14
    Sponsor Name:Haukeland University Hospital, Division of Psychiatry
    Full Title: The Bergen Psychosis Project 2
    Medical condition: Patients with schizophrenia and related non-affective psychotic disorders, corresponding to ICD-10 diagnoses F10.5-19.5, and F20-29.
    Disease: Version SOC Term Classification Code Term Level
    13.1 10037175 - Psychiatric disorders 10039628 Schizophrenia and other psychotic disorders HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2022-001865-11 Sponsor Protocol Number: TV44749-CNS-30096 Start Date*: 2023-03-08
    Sponsor Name:Teva Branded Pharmaceutical Products R&D, Inc.
    Full Title: A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo Controlled Study with an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Ola...
    Medical condition: Schizophrenia is a serious mental disorder in which people interpret reality abnormally. It is a severely debilitating psychotic disorder characterized by positive symptoms (eg, delusions, hallucin...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10039626 Schizophrenia PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BG (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-000788-34 Sponsor Protocol Number: 17303A Start Date*: 2017-11-08
    Sponsor Name:H. Lundbeck A/S
    Full Title: Interventional, randomized, double-blind, active-controlled study of the efficacy of Lu AF35700 in patients with early-in-disease or late-in-disease treatment-resistant schizophrenia
    Medical condition: Treatment-Resistant Schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004873 10072913 Treatment-resistant schizophrenia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-010276-16 Sponsor Protocol Number: F1D-MC-HGMX Start Date*: 2009-11-19
    Sponsor Name:Eli Lilly
    Full Title: A Long-Term, Open-Label, Safety Study of Oral Olanzapine in Adolescents with Bipolar I Disorder (Manic or Mixed Episodes) or Schizophrenia
    Medical condition: Bipolar I Disorder (Manic or Mixed Episodes) or Schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    13.1 10037175 - Psychiatric disorders 10039628 Schizophrenia and other psychotic disorders HLGT
    13.1 10037175 - Psychiatric disorders 10057667 Bipolar disorder PT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-004602-17 Sponsor Protocol Number: 031-201-00186 Start Date*: 2018-03-12
    Sponsor Name:Otsuka Pharmaceutical
    Full Title: A Multicentre, 8-week, Single-arm, Open-label, Pragmatic Trial to Explore Acceptance and Performance of Using a Digital Medicine System with Healthcare Professionals and Adult Subjects with Schizo...
    Medical condition: Schizophrenia, Schizoaffective Disorder, or First Episode Psychosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10039628 Schizophrenia and other psychotic disorders HLGT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-003820-40 Sponsor Protocol Number: D1050231 Start Date*: 2008-03-17
    Sponsor Name:Dainippon Sumitomo Pharma America, Inc.
    Full Title: A Phase 3 Randomized, Placebo- and Active Comparator-Controlled Clinical Trial to Study the Safety and Efficacy of Two Doses of Lurasidone HCl in Acutely Psychotic Patients with Schizophrenia
    Medical condition: Schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10039626 Schizophrenia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed)
    Trial results: View results
    EudraCT Number: 2007-007083-22 Sponsor Protocol Number: 37822681SCH2002, INT-1, 10 FEB 2009 Start Date*: 2008-10-01
    Sponsor Name:Janssen-Cilag International NV, Turnhoutseweg 30, 2340 Beerse, Belgium
    Full Title: A Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of 3 Fixed Doses of JNJ-37822681 Administered Twice Daily in Subjects With Schiz...
    Medical condition: Schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10039626 Schizophrenia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: LT (Completed) EE (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2016-000565-23 Sponsor Protocol Number: 2016-867 Start Date*: 2017-03-03
    Sponsor Name:
    Full Title: TAILOR - a randomized clinical trial: Tapered discontinuation versus maintenance therapy of antipsychotic medication in patients with newly diagnosed schizophrenia or schizophreniform psychosis in ...
    Medical condition: Patients with newly diagnosed schizophrenia or schizophreniform psychosis in remission of psychotic symptoms
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10038631 Residual schizophrenia, in remission LLT
    20.0 10037175 - Psychiatric disorders 10039628 Schizophrenia and other psychotic disorders HLGT
    20.0 100000004865 10065155 Treatment withdrawal LLT
    20.0 10037175 - Psychiatric disorders 10037243 Psychosis paranoid LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-005399-16 Sponsor Protocol Number: ROAC2014 Start Date*: 2014-08-05
    Sponsor Name:Dr. Benedicto Crespo. Servicio Psiquiatría. Hospital Universitario Marqués de Valdecilla/IDIVAL
    Full Title: Randomized, flexible-dose, open-label comparison to investigate the effectivenes of second generation antipsychotics in first episode psychosis patients.
    Medical condition: FIRST EPISODE DRUG-NAÏVE OF PSYCHOSIS (SCHIZOPHRENIA SPECTRUM DISORDERS)
    Disease: Version SOC Term Classification Code Term Level
    17.0 10037175 - Psychiatric disorders 10039628 Schizophrenia and other psychotic disorders HLGT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-003369-16 Sponsor Protocol Number: GWAP19030 Start Date*: 2020-06-02
    Sponsor Name:GW Research Ltd.
    Full Title: A Randomized, Double-blind, Parallel-group Trial to Investigate the Safety and Efficacy of GWP42003-P Versus Placebo as Adjunctive Therapy in Participants with Schizophrenia Experiencing Inadequate...
    Medical condition: Schizophrenia is neurodevelopmental syndrome, results from gradual alterations in brain connectivity. Can persist for years before psychosis emerges. Individuals have a 2 to 3 fold increased risk o...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-020987-39 Sponsor Protocol Number: 31-09-266 Start Date*: 2012-10-15
    Sponsor Name:Otsuka Pharmaceutical Development & Commercialization, Inc.
    Full Title: A Long-Term Multicenter, Randomized, Double-blind, Placebocontrolled Study to Evaluate the Efficacy, Safety, and Tolerability of Aripiprazole (OPC-14597) as Maintenance Treatment in Adolescent Pati...
    Medical condition: Schizophrenia in Adolescent Patients
    Disease: Version SOC Term Classification Code Term Level
    14.1 10037175 - Psychiatric disorders 10039626 Schizophrenia PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Jun 06 19:10:13 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA